Candid Therapeutics Acquired by UCB | Healthcare M&A Deal

UCB has completed the acquisition of Candid Therapeutics, a substance abuse treatment business in the healthcare sector, for $2B. Candid Therapeutics is developing two clinical-stage T cell engagers aimed at autoimmune indications, expanding UCB’s immune system pipeline. UCB acquisitions in this area support a strategic acquisition strategy to broaden immunology capabilities and strengthen future product development. The merger acquisition is announced as a strategic acquisition by UCB, and Candid Therapeutics terminated its reverse merger with Rallybio to accept UCB’s offer.